0001127602-21-014509.txt : 20210427
0001127602-21-014509.hdr.sgml : 20210427
20210427161741
ACCESSION NUMBER: 0001127602-21-014509
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210426
FILED AS OF DATE: 20210427
DATE AS OF CHANGE: 20210427
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zaks Tal Zvi
CENTRAL INDEX KEY: 0001690927
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 21859146
MAIL ADDRESS:
STREET 1: C/O ADAPTIMMUNE THERAPEUTICS PLC
STREET 2: 60 JUBILEE AVE, MILTON PARK
CITY: ABINGDON, OXFORDSHIRE
STATE: X0
ZIP: OX14 4RX
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2021-04-26
0001682852
Moderna, Inc.
MRNA
0001690927
Zaks Tal Zvi
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
Chief Medical Officer
Common Stock
2021-04-26
4
M
0
5000
12.21
A
5000
D
Common Stock
2021-04-26
4
S
0
580
169.87
D
4420
D
Common Stock
2021-04-26
4
S
0
439
171.05
D
3981
D
Common Stock
2021-04-26
4
S
0
1
171.65
D
3980
D
Common Stock
2021-04-26
4
S
0
200
173.03
D
3780
D
Common Stock
2021-04-26
4
S
0
400
175.03
D
3380
D
Common Stock
2021-04-26
4
S
0
551
175.97
D
2829
D
Common Stock
2021-04-26
4
S
0
900
177.41
D
1929
D
Common Stock
2021-04-26
4
S
0
1829
178.51
D
100
D
Common Stock
2021-04-26
4
S
0
100
179.37
D
0
D
Stock Option (Right to Buy)
12.21
2021-04-26
4
M
0
5000
0
D
2027-10-03
Common Stock
5000
146282
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.46 to $170.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.61 to $171.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $172.66 to $173.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $174.54 to $175.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $175.70 to $176.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $176.92 to $177.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $178.06 to $178.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).
/s/ Brian Sandstrom, as Attorney-in-Fact
2021-04-27